Cost-Effectiveness Analysis and Budget Impact: Antimuscarinics and Mirabegron for the Treatment of Patients With Urge Urinary Incontinence: The Brazilian Public Health System Perspective
| Autor: | Daniel da Silva Pereira, Gustavo Laine Araújo de Oliveira, Fernando Zanghelini, Thales B. C. Silva, Haliton Alves de Oliveira |
|---|---|
| Rok vydání: | 2019 |
| Předmět: |
Adult
Male medicine.medical_specialty Urge urinary incontinence Cost-Benefit Analysis Economics Econometrics and Finance (miscellaneous) Urinary incontinence Muscarinic Antagonists 03 medical and health sciences 0302 clinical medicine medicine Darifenacin Humans 030212 general & internal medicine Oxybutynin Pharmacology Toxicology and Pharmaceutics (miscellaneous) health care economics and organizations Solifenacin business.industry 030503 health policy & services Health Policy Urinary Incontinence Urge Cost-effectiveness analysis Middle Aged Thiazoles Physical therapy Urological Agents Acetanilides Female Tolterodine Public Health medicine.symptom 0305 other medical science Mirabegron business Brazil medicine.drug |
| Zdroj: | Value in health regional issues. 23 |
| ISSN: | 2212-1102 |
| Popis: | Objectives The Brazilian public health system does not cover pharmacotherapy for urge urinary incontinence (UUI). The aim of this study was to estimate the cost-effectiveness and budget impact of providing tolterodine, solifenacin, oxybutynin (OXY), darifenacin, and mirabegron for the treatment of UUI in Brazilian public health system. Methods A cost-effectiveness analysis with budget impact was performed. Six scenarios were assessed: in one scenario, all 5 therapeutic alternatives approved for coverage, and in the remaining 5 scenarios, only 1 alternative is approved for adoption for all patients. Clinical data were derived from a rapid systematic review conducted in several databases. One-way sensitivity analysis was also performed. The time horizon was 12 months. Results The cost-effectiveness analysis showed that patients treated with OXY had the lowest incremental cost-effectiveness ratio (ICER) per outcomes assessed (change in urinary incontinence episodes (UIE): R$1180.08; change in urge incontinence episodes: R$757.85 and change in micturition frequency: R$907.75), corresponding to a budget impact of R$17.9 billion over 5 years. The change in effectiveness measures was the parameter that most influenced the results of the ICER per patient-year. Conclusion The results of the study have shown that OXY and solifenacin had the lowest ICER per patient-year and the lowest budget impact when compared with other drugs. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|
Full Text from ScienceDirect